MorphoSys Keeps The Faith Despite Mixed Data For Myelofibrosis Combo

The jury is out on whether regulators have seen enough to approve pelabresib.

MorphoSys
• Source: MorphoSys

While MorphoSys AG CEO Jean-Paul Kress believes the German biotech has a blockbuster on its hands with pelabresib, the firm could still have a tricky time ahead with regulators following the release of mixed data for its closely watched candidate to treat myelofibrosis.

The Munich-based group has presented topline results from the Phase III MANIFEST-2 trial which was evaluating pelabresib, an investigational BET...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

More from Therapy Areas